REGENXBIO Presents Positive Initial Data from Phase II AAVIATE® Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery and Provides Trial Update at Retina Society 54th Annual Scientific Meeting
Retrieved on:
Friday, October 1, 2021
Securities Act of 1933, Perception, Cohort, AMD, Macular degeneration, Johns Hopkins Hospital, Death, Growth, GC, Neutralizing antibody, Injection, Safety, AAV, SEC, Technology, Screening, Drug Quality and Security Act, U.S. Securities and Exchange Commission, Webcast, Retina, Phase, Analysis, Diabetic retinopathy, Consultant, Result, Clinical trial, Patient, Risk, Annual report, Conversation, CRT, Health, Eye, Șaeș, Intention, Ranibizumab, Financial condition report, Johns Hopkins School of Medicine, Visual acuity, Severe cognitive impairment, QF 4.7-inch Mk I – IV naval gun, VEGF, COVID-19, NAV, Securities Exchange Act of 1934, Pharmaceutical industry, Medical device, Vaccine
REGENXBIO Inc. (Nasdaq: RGNX) today announced initial data from the ongoing Phase II AAVIATE trial of RGX-314 for the treatment of wet age-related macular degeneration (wet AMD) using in-office suprachoroidal delivery.
Key Points:
- REGENXBIO Inc. (Nasdaq: RGNX) today announced initial data from the ongoing Phase II AAVIATE trial of RGX-314 for the treatment of wet age-related macular degeneration (wet AMD) using in-office suprachoroidal delivery.
- "These are the first data ever reported from a gene therapy delivered to the suprachoroidal space of the eye in a clinical trial," said Dr. London.
- AAVIATE is a multi-center, open-label, randomized, active-controlled, dose-escalation trial that will evaluate the efficacy, safety and tolerability of suprachoroidal delivery of RGX-314 using the SCS Microinjector.
- SCS Microinjector is a trademark of Clearside Biomedical, Inc. All other trademarks referenced herein are registered trademarks of REGENXBIO.